Research and development daily Dongsun 3 diabetes compound preparations will be approved two impact first imitation.

2020.08.17 Research and Development NEWS: Phase ASC22II.a clinical trial completes the first batch of hepatitis B patients; the first new crown vaccine patent in China is approved; Bayer's "Chlorinated radon 223Ra injection" is about to be approved in China; Andin/Baiji Shenzhou CD3/BCMA dual-specific antibodies are approved clinically in China... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) "Drug Research and Development" ASC22II.a phase clinical trial completed the first case of hepatitis B patients drug administration Goli announced today: ASC22II.a phase clinical trial completed the first case of hepatitis B patients.
ASC22 is the world's first pD-L1 antibody to be injected under the skin.
Drug Approval: The first new crown vaccine patent in China has been approved according to the State Intellectual Property Office, and the patent application for the new crown vaccine jointly filed by Chen Wei, a member of the Military Medical Research Institute of the Academy of Military Sciences of the Academy of Military Sciences, and Concino Bio has been granted a patent right, thus becoming the first new crown vaccine patent in China.
the patent name is "a recombined new coronavirus vaccine based on human reproduction defect adenovirus".
day before the FDA approved Roche's innovative IL-6 inhibitor for market, Roche's Genente announced that the FDA had approved Enspryng's listing to treat adult patients with AQP4 antibody-positive visual neurospinal cord disease spectrum disorder.
Cenegermin eye drops were approved in China recently, Cenegermin eye drops were approved in China to treat neurotrophic corneitis.
the drug, developed by Dompé Pharmaceuticals, is one of the first clinically urgent overseas drugs.
East Sunshine 3 diabetes compound preparations will be approved on the 15th, East Sunshine 3 new class 4 diabetes products (Liglitatin metformin tablets, segritin tablets and siggritin tablets) listing applications into the "in the approval" stage, is expected to be formally approved recently.
addition, Liglitatin metformin tablets and siglitatin metformin tablets are the fastest-growing in the country and are expected to impact the first imitation.
today 5 new drugs approved clinically from Johnson and Johnson, Anjin / Baiji Shenzhou, Junshi biological ... CDE's latest announcement, a number of new drugs have been approved by clinical trials, including Amgen and Baiji Shenzhou jointly declared BCMA dual resistance, Johnson and Johnson's Janssen Pharmaceuticals developed anti-NKG2D monoclonal antibody, Regen bioPD-1 antibody Ripley monoanti, as well as Shenzhou cell VEGF monoantigen and PD-1 monoantigen and so on.
Koren Pharmaceutical injection yew alcohol (albumin binding type) will be approved on the 17th, Colum Pharmaceuticals submitted four types of generic drug injection yew alcohol (albumin binding type) market application into the administrative approval stage, is expected to be formally approved in the near future.
Bayer's "Chlorinated Radon 223Ra Injection" is about to be approved in China, Bayer submitted in China, the application for the listing of chlorinated radon 223Ra injection entered the "in-approval" stage, is expected to be approved in the near future to treat prostate cancer bone metastasis.
Haisco acetic acid capofen net access to the "drug registration certificate" 17, Hesco issued a notice that the wholly-owned subsidiary Liaoning Haisco recently received the State Drug Administration issued by the injection of acetic acetate capofen net "drug registration certificate."
-adaptive disorders are suitable for adult and child patients (three months and more): suspected fungal infections in patients with neogenic granulocyte reduction and fever; Candinaemia and the following Candina infections: abdominal abscesses, peritonitis and thoracic infections; esophageal candioccal disease; and invasive ascertic mold disease in patients who are ineffective or unable to withstand other treatments.
Anjin/Baiji Shenzhou CD3/BCMA dual-specific antibody was approved clinically in China on the 17th, Anjin/Baiji Shenzhou CD3/BCMA dual-specific antibody AMG 701 was approved clinically in China for the treatment of recurring/resusable multiple myeloma.
Fosun Pharma's hydrochloric acid amitriline tablet evaluation 16, Fosun Pharma announced that the controlling subsidiary Hunan Dongting Pharmaceutical Industry received the State Drug Administration issued on the hydrochloric acid amitrilin tablet "drug supplemental application approval notice", the drug through generic drug quality and efficacy consistent evaluation, the company for the product's first evaluation enterprise.
tablets Class 1 new drug PZH2109 capsule listing application was accepted on the 15th, Chipotleannounced that class 1 new drug PZH2109 capsule declared clinically obtained CDE acceptance, the drug is mainly used to treat non-alcoholic fatty hepatitis, the United States and China do not have the same target of the same adaptive drug was approved for market.
.